BIND Therapeutics, Inc. (Nasdaq – BIND), a clinical-stage nanomedicine platform company development novel targeted therapeutic, primarily for the treatment of cancer, and its affiliate BIND Biosciences Security Corporation, have filed a chapter 11 petitions before the United States Bankruptcy Court for the District of Delaware (Lead Case No. 16-11084).  The cases have been assigned to the Honorable Brendan L. Shannon.  The debtors have filed a motion seeking authority to use cash collateral.  The petitions (including the consolidated list of top 26 creditors), the first day declaration and the docket are available through Prime Clerk.  The debtors have issued a press release regarding their reorganization efforts.

Contact Norman L. Pernick, Nicholas J. Brannick, or David W. Giattino for more information.